FDA approves Ongentys an add-on treatment to levodopa/carbidopa in patients with Parkinson’s disease experiencing “off” episodes.- Neurocrine Biosciences.
Neurocrine Biosciences, Inc. announced that the FDA has approved once-daily oral Ongentys (opicapone) 25 mg and 50 mg capsules as an add-on treatment to levodopa/carbidopa in patients with… read more.